[HTML][HTML] European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

I Vergote, A González-Martín, I Ray-Coquard, P Harter… - Annals of …, 2022 - Elsevier
Background Homologous recombination repair (HRR) enables fault-free repair of double-
stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade …

[HTML][HTML] BRCA1-and BRCA2-associated hereditary breast and ovarian cancer

N Petrucelli, MB Daly, T Pal - 2022 - europepmc.org
BRCA1-and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is
characterized by an increased risk for female and male breast cancer, ovarian cancer …

ACMG SF v3. 0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and …

DT Miller, K Lee, WK Chung, AS Gordon… - Genetics in …, 2021 - nature.com
Clinicians are encouraged to document the reasons for the use of a particular procedure or
test, whether or not it is in conformance with this statement. Clinicians also are advised to …

TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes

NM Tung, ME Robson, S Ventz… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …

A population-based study of genes previously implicated in breast cancer

C Hu, SN Hart, R Gnanaolivu, H Huang… - … England Journal of …, 2021 - Mass Medical Soc
Background Population-based estimates of the risk of breast cancer associated with
germline pathogenic variants in cancer-predisposition genes are critically needed for risk …

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline☆

C Sessa, J Balmaña, SL Bober… - Annals of …, 2023 - annalsofoncology.org
Hereditary breast and ovarian cancer syndrome (HBOC) is clinically defined by family
history criteria, and molecularly defined by identification of germline pathogenic variants …

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

X Yang, H Song, G Leslie, C Engel… - JNCI: Journal of the …, 2020 - academic.oup.com
Background The purpose of this study was to estimate precise age-specific tubo-ovarian
carcinoma (TOC) and breast cancer (BC) risks for carriers of pathogenic variants in RAD51C …

Male breast cancer: an update

S Fox, V Speirs, AM Shaaban - Virchows Archiv, 2022 - Springer
Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the
incidence has increased worldwide. Risk factors include increased longevity, obesity …

Germline testing in patients with breast cancer: ASCO–Society of Surgical Oncology Guideline

I Bedrosian, MR Somerfield, MI Achatz… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE To develop recommendations for germline mutation testing for patients with
breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to …

Homologous recombination deficiency: cancer predispositions and treatment implications

MR Toh, J Ngeow - The oncologist, 2021 - academic.oup.com
Homologous recombination (HR) is a highly accurate DNA repair mechanism. Several HR
genes are established cancer susceptibility genes with clinically actionable pathogenic …